To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

PHASE3Enrolling by invitationINTERVENTIONAL

Enrollment

125

Participants

Timeline

Start Date

April 22, 2025

Primary Completion Date

May 19, 2025

Study Completion Date

December 31, 2028

Conditions

HypertensionPrimary Hypercholesterolaemia

Interventions

DRUG

Ezetimibe/Rosuvastatin/Candesartan/Amlodipine

PO, QD, 8 weeks

DRUG

Candesartan/Amlodipine

PO, QD, 8 weeks

DRUG

Candesartan/Rosuvastatin/Ezetimibe

PO, QD, 8 weeks

Trial Locations (1)

Hanyang University Hospital, Seoul